Through its Policy Leadership Forum, ICER convenes leading health care organizations to shape the future of evidence-based policy in the US.
Policy Leadership Forum members work together in a non-adversarial environment to contribute to the development of influential policy recommendations and provide insights into methods to strengthen real world application of evidence-based policy.
ICER selects Forum members with the goal of maintaining balance across industries to represent a broad range of organizational perspectives. Dues go to Forum-specific activities and do not fund ICER reports. Participation in the program does not provide members with influence into ICER’s health technology assessments.
For more information on becoming a member of the Policy Leadership Forum, please contact Amanda Mehlman, Director of Strategic Partnerships.
INTERESTED IN THE POLICY LEADERSHIP FORUM?
ICER has a limited number of spots for Standard and Flagship members. For more information, see ICER Policy Leadership Forum Overview
If you are interested in applying for the Policy Leadership Forum, please express interest to Amanda Mehlman. The next Policy Leadership Forum membership cycle will begin on July 1, 2024.
ICER hosts senior leaders from Forum companies for an annual meeting to deliberate on important issues related to comparative effectiveness research, technology assessment, coverage decision-making, and health care financing. ICER incorporates key policy recommendations produced at the meetings into white papers for peer-reviewed publication. Please find ICER’s white papers for 2016-2023 below.
Current Policy Leadership Forum Members
- Alnylam Pharmaceuticals
- America’s Health Insurance Plans (AHIP)
- Bayer Healthcare LLC
- Blue Shield of CA
- Boehringer Ingelheim
- CRISPR Therapeutics
- CVS Caremark
- Envolve Pharmacy Solutions
- Express Scripts
- Health Care Service Corporation (HCSC)
- Kaiser Permanente
- Karuna Therapeutics
- LEO Pharma
- Mallinckrodt Pharmaceuticals
- Merck & Co.
- National Pharmaceutical Council (NPC)
- Novo Nordisk
- Otsuka Pharmaceutical
- Premera Blue Cross
- Prime Therapeutics
- Sun Life Financial